Hanmi's Eppe is due this month at 129,800 won wholesale for four weeks, against about 210,000 to 270,000 won for Wegovy and Mounjaro. At the 299,200 won maintenance dose, Seoul Economic Daily puts the gap at 17% to 19%.
Perspective Coverage
3 publishers
- Builder
- Builder 13%
- Operator
- Operator 37%
- Investor
- Investor 50%
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+35
- Incentives60
- Confidence62
Korea's regulator approved Hanmi Pharmaceutical's efpeglenatide, the first homegrown GLP-1 obesity drug, after patients lost 9.02% of body weight in 40 weeks. That is less than Wegovy and Mounjaro showed in longer trials, so Hanmi's case rests on milder side effects and a price for long-term patients that it has not yet set.
Reality
- Evidence60
- Adoption8
- Hype gap+15
- Incentives60
- Confidence58
Price decides whether Hanmi's Eppe takes share from Mounjaro and Wegovy
Hanmi Pharmaceutical's Eppe, Korea's first home-grown GLP-1 obesity drug, is approved and expected to launch at about half Wegovy's 200,000-won-plus price. Its trial weight loss trails both incumbents, so the launch price will set how much of a Mounjaro-dominated market it can reach.
Reality
- Evidence55
- Adoption8
- Hype gap+10
- Incentives40
- Confidence50
Hanmi's Cheaper Obesity Drug Eppe Could Undercut Lilly's Mounjaro More Than Novo's Wegovy
Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Not scored
- Hype gap+25
- Incentives
- Not scored
- Confidence40
AriBio's Phase 3 readout decides whether Fosun pays another $80 million for AR1001
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+20
- Incentives70
- Confidence45
FDA investigates possible link between GLP-1 drugs and rare eye condition amid New Jersey lawsuits
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
- Evidence45
- Adoption74
- Hype gap+14
- Incentives62
- Confidence42
Hanmi and Chong Kun Dang added half of Korea's 97.1 billion won drug R&D increase
Thirty of Korea's most exposed drugmakers raised first-half R&D by about a fifth as next year's generic price cuts approach, and the two largest spenders in the group supplied most of the increase. Four smaller firms cut.
Reality
- Evidence62
- Adoption58
- Hype gap+16
- Incentives70
- Confidence58
Genentech pays Hanmi 2.5 times Lilly's upfront for an asset one trial phase behind
Two out-licensing deals in three months put 375.8 billion won of upfront cash on Hanmi's books, about 1.5 times last year's operating profit, and it was the obesity candidate still in Phase 1 that priced richest.
Reality
- Evidence48
- Adoption68
- Hype gap+34
- Incentives66
- Confidence54
Korea's big five pharma put 12.4% of sales into R&D, and three of them set it by formula
Combined first-half research spending reached 562.8 billion won. Chong Kun Dang's 37% jump supplied nearly 40% of the group's increase, and the filings carry no profit lines to weigh it against.
Reality
- Evidence68
- Adoption62
- Hype gap+14
- Incentives72
- Confidence60